Zhang, J., et al., Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management
Fully Decentralized Model The fully decentralized model accounts for 31.3% of the 2025 market at a 13.5% CAGR, representing a trial design framework in which all or virtually all study activities including recruitment, informed consent, investigational product dispensing, safety assessments, and endpoint data collection are conducted without requiring participants to visit a fixed investigational site
ML: Molecular layer
Staying hydrated is essential to combating this specific issue
Despite these restrictions, many compounding pharmacies continue to market semaglutide sodium and semaglutide acetate, which are not legally permitted substitutes for the approved semaglutide molecule
Waller R, Wyles M, Heath PR, Kazoka M, Wollff H, Shaw PJ, et al